was founded in 2013 to develop novel compounds that are effective on both drug-resistant tumors and cancer stem cells.  In numerous preclinical models of cancer, including colon, pancreatic, prostate, breast and lung cancers the company’s lead product SBT-1214 has shown to completely eliminate the tumor.  Additional studies have shown that SBT-1214 is able to effectively down-regulate “stemness” gene expression and kill cancer stem cells.  Additional chemical modifications and a novel fatty-acid based nanoemulsion formulation result in a drug that has improved pharmacokinetics and pharmacodynamics properties as well as reduced toxicity.
TargaGenix New Chemical Entity (NCE) for use in oncology
  • Unique chemical composition makes the compound effective in Multi-drug resistanttumor models
  • Effective in killing cancer stem cells
  • Novel formulation removes the need for a toxic excipient, improved pharmacokinetics, improved pharmacodynamics, improved retention, reduced toxicity and passive targeting to the tumor interstitium.
  • Potential to be in clinic in 12-18 months from initiation of CMC and IND campaign
  • $2.3 million in funding from NCI for development of cancer stem cell therapeutics
  • $8 million to completion of Phase 1/2 clinical program in
  • Significant value creation
  • High margin potential based on current oncology pricing and manufacturing cost
  • Composition of Matter IP protection on drug & formualtion
Meet Our Management Team
Scientific Publications
Show More
For further information please contact us.

We are here to assist. Contact us by phone, email or via our social media channels.


@ 2016 TargaGenix, Inc. All Rights Reserved.

  • Black Facebook Icon
  • Black Twitter Icon
  • Black LinkedIn Icon